RT Journal Article
SR Electronic
T1 Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.02.20082461
DO 10.1101/2020.05.02.20082461
A1 Shah, Sachin J.
A1 Barish, Peter N.
A1 Prasad, Priya A.
A1 Kistler, Amy
A1 Neff, Norma
A1 Kamm, Jack
A1 Li, Lucy M.
A1 Chiu, Charles Y.
A1 Babik, Jennifer M.
A1 Fang, Margaret C.
A1 Kangelaris, Kirsten Neudoerffer
A1 Langelier, Charles
A1 ,
A1 Abe-Jones, Yumiko
A1 Alipanah, Narges
A1 Alvarez, Francisco N.
A1 Botvinnik, Olga Borisovna
A1 Castaneda, Gloria
A1 ,
A1 Dadasovich, Rand M.
A1 Davis, Jennifer
A1 Deng, Xianding
A1 DeRisi, Joseph L.
A1 Detweiler, Angela M.
A1 Federman, Scot
A1 Haliburton, John
A1 Hao, Samantha
A1 Kerkhoff, Andrew D.
A1 Kumar, G. Renuka
A1 Malcolm, Katherine B.
A1 Mann, Sabrina A.
A1 Martinez, Sandra
A1 Marya, Rupa K.
A1 Mick, Eran
A1 Mwakibete, Lusajo
A1 Najafi, Nader
A1 Peluso, Michael J.
A1 Phelps, Maira
A1 Pisco, Angela Oliveira
A1 Ratnasiri, Kalani
A1 Rubio, Luis A.
A1 Sellas, Anna
A1 Sherwood, Kyla D.
A1 Sheu, Jonathan
A1 Spottiswoode, Natasha
A1 Tan, Michelle
A1 Yu, Guixia
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.02.20082461.abstract
AB Background Emerging data on the clinical presentation, diagnostics, and outcomes of patients with COVID-19 have largely been presented as case series. Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses.Methods We examined all patients presenting to an emergency department in San Francisco, California between February 3 and March 31, 2020 with an acute respiratory illness who were tested for SARS-CoV-2. We determined COVID-19 status by PCR and metagenomic next generation sequencing (mNGS). We compared demographics, comorbidities, symptoms, vital signs, and laboratory results including viral diagnostics using PCR and mNGS. Among those hospitalized, we determined differences in treatment (antibiotics, antivirals, respiratory support) and outcomes (ICU admission, ICU interventions, acute respiratory distress syndrome, cardiac injury).Findings In a cohort of 316 patients, 33 (10%) tested positive for SARS-CoV-2; 31 patients, all without COVID-19, tested positive for another respiratory virus (16%). Among patients with additional viral testing, no co-infections with SARS-CoV-2 were identified by PCR or mNGS. Patients with COVID-19 reported longer symptoms duration (median 7 vs. 3 days) and were more likely to report fever (82% vs. 44%) fatigue (85% vs. 50%) and myalgias (61% vs 27%); p<0.001 for all comparisons. Lymphopenia (55% vs 34%, p=0.018) and bilateral opacities on initial chest radiograph (55% vs. 24%, p=0.001) were more common in patients with COVID-19. Patients with COVID-19 were more often hospitalized (79% vs. 56%, p=0.014). Of 186 hospitalized patients, patients with COVID-19 had longer hospitalizations (median 10.7d vs. 4.7d, p<0.001) and were more likely to develop ARDS (23% vs. 3%, p<0.001). Most comorbidities, home medications, signs and symptoms, vital signs, laboratory results, treatment, and outcomes did not differ by COVID-19 status.Interpretation While we found differences in clinical features of COVID-19 compared to other acute respiratory illnesses, there was significant overlap in presentation and comorbidities. Patients with COVID-19 were more likely to be admitted to the hospital, have longer hospitalizations and develop ARDS, and were unlikely to have co-existent viral infections. These findings enhance understanding of the clinical characteristics of COVID-19 in comparison to other acute respiratory illnesses.Competing Interest StatementDr. Prasad reports personal fees from EpiExcellence, LLC, outside the submitted work. Dr. Chiu reports grants from National Institutes of Health/NHLBI, grants from National Institutes of Health/NIAID, during the conduct of the study. Dr. Peluso reports grants from Gilead Sciences, outside the submitted work. Dr. Deng has a patent 62/667344 pending.Funding StatementThis study was supported by the National Center for Advancing Translational Sciences (KL2TR001870), the National Heart Lung Blood Institute (1K23HL138461-01A1, R01-HL105704), National Institute of Allergy and Infectious Diseases (T32 AI060530, R33-AI120977), the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesViral genomic data is publicly accessible via gisaid.org (Global Initiative on Sharing All Influenza Data) 36 and Genbank (MT385414 - MT385497).